舒利迭治疗中-重度稳定期老年慢性阻塞性肺疾病的最佳剂量

目的 探究舒利迭治疗中-重度稳定期老年慢性阻塞性肺疾病(COPD)的最佳剂量.方法 选取2013年5月至2015年5月本院收治的老年中-重度稳定期COPD患者132例,根据治疗方法分为对照组(常规治疗)、小剂量组(舒利迭50/250μg)和大剂量组(舒利迭50/500μg),每组44例.比较3组临床疗效.结果 治疗后,3组FEV1、FEV1/FVC、FEV1％、6-MWD和临床症状评分较治疗前均明显改善(P＜0.05),且各组间差异有统计学意义(P＜ 0.05),其中大剂量组最优;治疗后,大剂量组和小剂量组PaO2显著升高,PaC02显著降低(P＜0.05),且大剂量组Pa02与PaC02变化程度显著高于小剂量组(P＜0.05).结论 舒利迭在改善老年COPD中-重度稳定期患者的肺功能、临床症状等方面效果确切,而大剂量更具优势.

Optimal dose of seretide in treatment of elderly patients with chronic obstructive pulmonary disease (COPD)in moderate to severe stable period

Objective To explore the optimal dose of seretide for senile chronic obstructive pulmonary disease (COPD) in moderate to severe stable period.Methods 132 patients with moderate to severe stable COPD treated at our hospital from May,2013 to May,2015 were selected and divided into a control group (conventional therapy),a small dose group (seretide 50/250 μg),and a large dose group (seretide 50/500 μg) according to different treatment methods,44 cases for each group.The clinical efficacies were compared between these 3 groups.Results The FEV1,FEV1/FVC,FEV1％,6-MWD,and clinical symptom score were significantly better after than before the treatment in all the three groups (P＜0.05) and were best in the large dose group after the treatment,with statistical differences between these three groups (P＜0.05).After the treatment,PaO2 significantly increased and PaCO2 significantly decreased in the small dose group and the large dose group (P＜0.05) and the changes of PaO2 and PaCO2 were significantly higher in the large dose group than in the small dose group (P＜0.05).Conclusion Seretide can significantly improve pulmonary function,clinical symptoms,and so on of the elderly moderate to severe stable COPD patients and large dose has more advantages.